Contemporary Encephalitis Lethargica: Phenotype, laboratory findings and treatment outcomes

Roberto Lopez Alberola, Mike Georgiou, George N Sfakianakis, Carlos Singer, Spyridon Papapetropoulos

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background : Encephalitis lethargica (EL) is a CNS disorder that manifests with lethargy sleep cycle disturbances, extrapyramidal symptomatology, neuropsychiatric manifestations, ocular features and cardio-respiratory abnormalities. Although there have been no reported outbreaks of EL recently, a number of reports show that cases of EL are still encountered regularly. Against this background we conducted a study aiming to elucidate the clinical characteristics, describe laboratory/ neuroimaging findings (MRI, PET) and present treatment options and outcomes in sporadic EL. Methods : Patients were diagnosed over a period of 3 years using proposed diagnostic criteria. Extensive laboratory and imaging tests were performed for exclusion of other causes. Anti-neuronal antibodies against human basal ganglia were detected with western immunoblotting and 18F-FDG PET imaging was performed. Selected cases were videotaped. Results : Our patients (M/F: 5/3) ranged from 2-28 years (mean 9.3 ± 9.5). Encephalopathy, sleep disturbances and extrapyramidal symptoms were present in all cases. Laboratory investigations revealed CSF leukocytosis in 5/8 patients and anti-BG Ab in 4/7 patients. MRIs revealed structural abnormalities in 7/8 cases. 18F-FDG PET showed basal ganglionic hypermetabolism in 4/7 patients. Treatment approaches included immunomodulating and symptomatic therapies. We report no mortality from EL in our series. Conclusions : There seems to be little doubt that cases of EL still occur. Diagnosis may be based on clinical suspicion and laboratory/imaging tests may lead to early initiation of immunomodulating and supporting therapies. We suggest that in addition to anti-BG Abs FDG PET should be considered as a diagnostic tool for EL.

Original languageEnglish
Pages (from-to)396-404
Number of pages9
JournalJournal of Neurology
Volume256
Issue number3
DOIs
StatePublished - Mar 1 2009

Fingerprint

Encephalitis
Phenotype
Fluorodeoxyglucose F18
Sleep
Lethargy
Leukocytosis
Brain Diseases
Basal Ganglia
Neuroimaging
Disease Outbreaks
Anti-Idiotypic Antibodies
Therapeutics
Western Blotting
Mortality

Keywords

  • Anti-basal ganglia antibodies
  • Encephalitis Lethargica
  • MRI
  • PET
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Contemporary Encephalitis Lethargica : Phenotype, laboratory findings and treatment outcomes. / Lopez Alberola, Roberto; Georgiou, Mike; Sfakianakis, George N; Singer, Carlos; Papapetropoulos, Spyridon.

In: Journal of Neurology, Vol. 256, No. 3, 01.03.2009, p. 396-404.

Research output: Contribution to journalArticle

@article{9b0da9fe370349da97f29116a1b5d0f9,
title = "Contemporary Encephalitis Lethargica: Phenotype, laboratory findings and treatment outcomes",
abstract = "Background : Encephalitis lethargica (EL) is a CNS disorder that manifests with lethargy sleep cycle disturbances, extrapyramidal symptomatology, neuropsychiatric manifestations, ocular features and cardio-respiratory abnormalities. Although there have been no reported outbreaks of EL recently, a number of reports show that cases of EL are still encountered regularly. Against this background we conducted a study aiming to elucidate the clinical characteristics, describe laboratory/ neuroimaging findings (MRI, PET) and present treatment options and outcomes in sporadic EL. Methods : Patients were diagnosed over a period of 3 years using proposed diagnostic criteria. Extensive laboratory and imaging tests were performed for exclusion of other causes. Anti-neuronal antibodies against human basal ganglia were detected with western immunoblotting and 18F-FDG PET imaging was performed. Selected cases were videotaped. Results : Our patients (M/F: 5/3) ranged from 2-28 years (mean 9.3 ± 9.5). Encephalopathy, sleep disturbances and extrapyramidal symptoms were present in all cases. Laboratory investigations revealed CSF leukocytosis in 5/8 patients and anti-BG Ab in 4/7 patients. MRIs revealed structural abnormalities in 7/8 cases. 18F-FDG PET showed basal ganglionic hypermetabolism in 4/7 patients. Treatment approaches included immunomodulating and symptomatic therapies. We report no mortality from EL in our series. Conclusions : There seems to be little doubt that cases of EL still occur. Diagnosis may be based on clinical suspicion and laboratory/imaging tests may lead to early initiation of immunomodulating and supporting therapies. We suggest that in addition to anti-BG Abs FDG PET should be considered as a diagnostic tool for EL.",
keywords = "Anti-basal ganglia antibodies, Encephalitis Lethargica, MRI, PET, Treatment",
author = "{Lopez Alberola}, Roberto and Mike Georgiou and Sfakianakis, {George N} and Carlos Singer and Spyridon Papapetropoulos",
year = "2009",
month = "3",
day = "1",
doi = "10.1007/s00415-009-0074-4",
language = "English",
volume = "256",
pages = "396--404",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "3",

}

TY - JOUR

T1 - Contemporary Encephalitis Lethargica

T2 - Phenotype, laboratory findings and treatment outcomes

AU - Lopez Alberola, Roberto

AU - Georgiou, Mike

AU - Sfakianakis, George N

AU - Singer, Carlos

AU - Papapetropoulos, Spyridon

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Background : Encephalitis lethargica (EL) is a CNS disorder that manifests with lethargy sleep cycle disturbances, extrapyramidal symptomatology, neuropsychiatric manifestations, ocular features and cardio-respiratory abnormalities. Although there have been no reported outbreaks of EL recently, a number of reports show that cases of EL are still encountered regularly. Against this background we conducted a study aiming to elucidate the clinical characteristics, describe laboratory/ neuroimaging findings (MRI, PET) and present treatment options and outcomes in sporadic EL. Methods : Patients were diagnosed over a period of 3 years using proposed diagnostic criteria. Extensive laboratory and imaging tests were performed for exclusion of other causes. Anti-neuronal antibodies against human basal ganglia were detected with western immunoblotting and 18F-FDG PET imaging was performed. Selected cases were videotaped. Results : Our patients (M/F: 5/3) ranged from 2-28 years (mean 9.3 ± 9.5). Encephalopathy, sleep disturbances and extrapyramidal symptoms were present in all cases. Laboratory investigations revealed CSF leukocytosis in 5/8 patients and anti-BG Ab in 4/7 patients. MRIs revealed structural abnormalities in 7/8 cases. 18F-FDG PET showed basal ganglionic hypermetabolism in 4/7 patients. Treatment approaches included immunomodulating and symptomatic therapies. We report no mortality from EL in our series. Conclusions : There seems to be little doubt that cases of EL still occur. Diagnosis may be based on clinical suspicion and laboratory/imaging tests may lead to early initiation of immunomodulating and supporting therapies. We suggest that in addition to anti-BG Abs FDG PET should be considered as a diagnostic tool for EL.

AB - Background : Encephalitis lethargica (EL) is a CNS disorder that manifests with lethargy sleep cycle disturbances, extrapyramidal symptomatology, neuropsychiatric manifestations, ocular features and cardio-respiratory abnormalities. Although there have been no reported outbreaks of EL recently, a number of reports show that cases of EL are still encountered regularly. Against this background we conducted a study aiming to elucidate the clinical characteristics, describe laboratory/ neuroimaging findings (MRI, PET) and present treatment options and outcomes in sporadic EL. Methods : Patients were diagnosed over a period of 3 years using proposed diagnostic criteria. Extensive laboratory and imaging tests were performed for exclusion of other causes. Anti-neuronal antibodies against human basal ganglia were detected with western immunoblotting and 18F-FDG PET imaging was performed. Selected cases were videotaped. Results : Our patients (M/F: 5/3) ranged from 2-28 years (mean 9.3 ± 9.5). Encephalopathy, sleep disturbances and extrapyramidal symptoms were present in all cases. Laboratory investigations revealed CSF leukocytosis in 5/8 patients and anti-BG Ab in 4/7 patients. MRIs revealed structural abnormalities in 7/8 cases. 18F-FDG PET showed basal ganglionic hypermetabolism in 4/7 patients. Treatment approaches included immunomodulating and symptomatic therapies. We report no mortality from EL in our series. Conclusions : There seems to be little doubt that cases of EL still occur. Diagnosis may be based on clinical suspicion and laboratory/imaging tests may lead to early initiation of immunomodulating and supporting therapies. We suggest that in addition to anti-BG Abs FDG PET should be considered as a diagnostic tool for EL.

KW - Anti-basal ganglia antibodies

KW - Encephalitis Lethargica

KW - MRI

KW - PET

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=65449165714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449165714&partnerID=8YFLogxK

U2 - 10.1007/s00415-009-0074-4

DO - 10.1007/s00415-009-0074-4

M3 - Article

C2 - 19412724

AN - SCOPUS:65449165714

VL - 256

SP - 396

EP - 404

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 3

ER -